MARKET

LRTX

LRTX

Lirum Therapeutics
NASDAQ
5.00
0.00
0.00%
Closed
OPEN
--
PREV CLOSE
5.00
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
46.35M
P/E (TTM)
-43.4028
1D
5D
1M
3M
1Y
5Y
1D
IPO Roundup: Ardent Health, TWFG, Artiva Biotherapeutics, and more
Seeking Alpha · 07/15/2024 16:12
Wall Street Breakfast: The Week Ahead
Seeking Alpha · 07/14/2024 12:03
Catalyst Watch: Netflix, Taiwan Semi, Amazon, and HashiCorp are in the spotlight
Seeking Alpha · 07/12/2024 19:00
IPO roundup: SLRA, OS, and more
Seeking Alpha · 07/01/2024 15:45
Lirum Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Benzinga · 05/09/2024 15:00
IPO Roundup: ZEEKR, Proficient Auto Logistics, and more
Seeking Alpha · 05/06/2024 14:00
U.S. IPO Weekly Recap: Viking Trades Up After Completing The Year's Largest US IPO To Date
Seeking Alpha · 05/04/2024 07:52
IPO Roundup: Viking Holdings, RanMarine Technology, and more
Seeking Alpha · 04/29/2024 13:33
More
About LRTX
Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. The Company’s lead product candidate, LX-101, is a novel, clinical-stage, precision-engineered targeted therapy directed to the insulin-like growth factor-1 (IGF-1) receptor (IGF-1R). The IGF-1/IGF-1R pathway is implicated in a host of malignancies and autoimmune diseases. LX-101 consists of an optimized, precision-engineered IGF-1 variant, with high affinity to IGF-1R and reduced affinity to IGF binding proteins (IGFBPs), coupled to the cytotoxic payload, methotrexate. Methotrexate is a cytotoxic inhibitor of DNA synthesis, repair, and cellular replication and is used to treat patients with certain cancers and autoimmune diseases, including TED.

Webull offers Lirum Therapeutics Inc stock information, including NASDAQ: LRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRTX stock methods without spending real money on the virtual paper trading platform.